The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSmith & Nephew Regulatory News (SN.)

Share Price Information for Smith & Nephew (SN.)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 996.80
Bid: 999.80
Ask: 1,000.50
Change: 11.20 (1.14%)
Spread: 0.70 (0.07%)
Open: 985.00
High: 1,006.00
Low: 984.20
Prev. Close: 985.60
SN. Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ECC endorsed by Royal College of Surgeons

18 Apr 2018 08:00

RNS Number : 2306L
Smith & Nephew Plc
18 April 2018
 

Smith & Nephew's Expert Connect Centre endorsed by Royal College of Surgeons18 April 2018

Smith & Nephew (LSE:SN, NYSE:SNN), the global medical technology business, is pleased to announce its state-of-the-art Expert Connect Centre ('ECC') in Watford, UK has become the first commercial surgical training facility in Europe to be accredited by the Royal College of Surgeons.

Widely regarded as the gold standard for accreditation, the Royal College of Surgeons endorsement follows an in-depth assessment of the facilities, resources and portfolio offered at the ECC. The recognition enables delegates to receive Continuing Professional Development (CPD) points when attending Smith & Nephew sessions, demonstrating their commitment to developing their surgical skills.

"Smith & Nephew's Expert Connect Centre offers facilities of the highest quality; its education portfolio is extensive and there was a clear demonstration and a broad confidence in each of the components assessed" said Professor Paul O'Flynn, Quality Assurance and Accreditation, Royal College of Surgeons.

"We're pleased to offer the ECC this accreditation and look forward to continue seeing the centre enable surgeons to achieve the highest standards of care."

"This endorsement from the Royal College of Surgeons is a huge honour and recognition of the quality of our medical training and education. We're very proud to be regarded as a benchmark professional development facility and look forward to welcoming more healthcare professionals to the Expert Connect Centre as we continue to support them in their vital work improving patients' lives," said Massimiliano Colella, President Europe and Canada, Smith & Nephew.

Since its opening in February 2017, almost 2000 healthcare professionals from the UK and across the globe, including Canada, Japan and China have received training at the ECC. Designed to encourage interaction, the centre offers the same set-up as 14 hospital operating rooms, providing an environment where surgeons and nurses can learn new techniques and refine skills first hand, to ensure the safe and effective use of Smith & Nephew products. It boasts a large auditorium, seating over 80, for plenary sessions and uses the latest broadcasting and recording technology to capture and share the learning experience.

- ends -

Enquiries

Media

Charles ReynoldsSmith & Nephew

Matt CopemanSmith & Nephew

+44(0)1923 477314

 

+44 (0)1923 477385

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2017 were almost $4.8 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).

For more information about Smith & Nephew, please visit our website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com.

 

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations. 

Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAEASLXFSPPEFF
Date   Source Headline
25th Mar 20199:00 amRNSRe-presented Historical Quarterly Revenue Analysis
13th Mar 20197:00 amRNSMulti-asset digital surgery and robotic ecosystem
12th Mar 20191:00 pmRNSSmith & Nephew to acquire Osiris Therapeutics, Inc
8th Mar 20191:31 pmRNSDirector/PDMR Shareholding
8th Mar 20191:29 pmRNSDirector/PDMR Shareholding
8th Mar 20191:27 pmRNSDirector/PDMR Shareholding
4th Mar 20194:08 pmRNSAnnual Financial Report
4th Mar 20193:42 pmRNSAnnual Financial Report
1st Mar 201911:43 amRNSTotal Voting Rights
19th Feb 20193:08 pmRNSTransaction in Own Shares
15th Feb 20195:32 pmRNSTransaction in Own Shares
14th Feb 20195:37 pmRNSTransaction in Own Shares
14th Feb 20198:14 amRNSDirector Declaration
13th Feb 20195:17 pmRNSTransaction in Own Shares
12th Feb 20195:20 pmRNSTransaction in Own Shares
11th Feb 20195:41 pmRNSTransaction in Own Shares
8th Feb 20191:59 pmRNSTransaction in Own Shares
8th Feb 20199:20 amRNSDirector/PDMR Shareholding
8th Feb 20199:17 amRNSDirectorate Change
7th Feb 20197:00 amRNSFinal Results
1st Feb 20192:04 pmRNSBlock listing Interim Review
1st Feb 201912:06 pmRNSTotal Voting Rights
22nd Jan 20192:38 pmRNSSmith & Nephew acquires Ceterix Orthopaedics
16th Jan 20195:19 pmRNSDirector/PDMR Shareholding
11th Jan 20199:00 amRNSNotice of Results
7th Jan 20197:00 amRNSSmith & Nephew to present today at JP Morgan
4th Jan 20195:32 pmRNSSmith & Nephew at JP Morgan Healthcare Conference
2nd Jan 201911:19 amRNSTotal Voting Rights
18th Dec 20184:30 pmRNSAcquisition
7th Dec 201810:26 amRNSDirector/PDMR Shareholding
4th Dec 20184:20 pmRNSDirector/PDMR Shareholding
4th Dec 20184:18 pmRNSDirector/PDMR Shareholding
3rd Dec 201812:00 pmRNSTotal Voting Rights
26th Nov 20183:07 pmRNSTransaction in Own Shares
22nd Nov 201811:57 amRNSTransaction in Own Shares
21st Nov 20185:31 pmRNSTransaction in Own Shares
20th Nov 20185:18 pmRNSTransaction in Own Shares
19th Nov 20185:49 pmRNSTransaction in Own Shares
16th Nov 20182:19 pmRNSDirector/PDMR Shareholding
16th Nov 201810:21 amRNSDirector/PDMR Shareholding
16th Nov 20188:59 amRNSTransaction in Own Shares
14th Nov 20184:46 pmRNSDirector/PDMR Shareholding
12th Nov 20183:46 pmRNSDirector/PDMR Shareholding
9th Nov 20184:26 pmRNSDirector/PDMR Shareholding
6th Nov 20188:55 amRNSDirector/PDMR Shareholding
5th Nov 20188:24 amRNSDirector/PDMR Shareholding
1st Nov 20184:26 pmRNSDirector/PDMR Shareholding
1st Nov 20183:20 pmRNSDirector/PDMR Shareholding
1st Nov 20183:00 pmRNSTotal Voting Rights
1st Nov 20187:00 amRNSTrading Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.